In the realm of targeted cancer therapies, alectinib and lorlatinib stand as prominent choices for treating specific types of lung cancer. Alectinib, an anaplastic lymphoma kinase (ALK) inhibitor, and lorlatinib, another ALK inhibitor, have garnered significant attention for their efficacy and potential side effects. This article delves into a comparative analysis of alectinib and lorlatinib,...